Skip to main content
. 2014 Jan 27;3(2):310–321. doi: 10.1002/cam4.185

Figure 5.

Figure 5

(A) CD34-positive microvessels 3 days after the treatment of fractionated radiation (FR) and Everolimus. Everolimus significantly decreased microvessel density in SAS-R tumors when combined with FR. Mean ± SD of three independent mice. (B) Everolimus-induced morphological changes of microvessels. (i–vi) Tomato lectin labeling of blood-circulating vessels followed by CD31 immunostaining. After 3 days of treatment, the discrepancy between tomato lectin and CD31 staining decreased in SAS-R tumors treated with Everolimus. In SAS-R tumors without Everolimus, tumor vessels acquired wide lumens. In contrast, lumen diameter did not decrease in SAS tumors. (i) SAS tumor without Everolimus. (ii) SAS tumor with Everolimus. (iii) SAS tumor with Everolimus. (iv) SAS-R tumor without Everolimus. (v) SAS-R tumor with Everolimus. (vi) SAS-R tumor with Everolimus. (vii–x) Representative vasculature ruptures in SAS-R tumors after FR and Everolimus treatment. (vii) A collapsed vessel with leaking tomato lectin satining. (viii) Type IV collagen staining showing the rupture of the basal membrane of vessels. (ix) CD31 immunohistochemistry. (v) vii–ix merged. Scale bur: 50 μm. FR, fractionated radiation.